Humacyte, Inc. (NASDAQ:HUMA) Receives $8.14 Average Target Price from Analysts

Humacyte, Inc. (NASDAQ:HUMA) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $8.1429.

HUMA has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of Humacyte in a research note on Monday, December 1st. UBS Group reiterated a “buy” rating on shares of Humacyte in a report on Monday, December 1st. D. Boral Capital restated a “buy” rating and set a $25.00 price target on shares of Humacyte in a research note on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Humacyte in a report on Monday, December 29th. Finally, Wall Street Zen lowered shares of Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday, December 21st.

Hedge Funds Weigh In On Humacyte

A number of hedge funds have recently added to or reduced their stakes in the stock. Endowment Wealth Management Inc. raised its stake in shares of Humacyte by 5.1% in the second quarter. Endowment Wealth Management Inc. now owns 109,458 shares of the company’s stock worth $229,000 after purchasing an additional 5,350 shares during the last quarter. Wealth Effects LLC grew its holdings in Humacyte by 5.8% during the second quarter. Wealth Effects LLC now owns 102,167 shares of the company’s stock worth $214,000 after buying an additional 5,600 shares in the last quarter. ProShare Advisors LLC raised its position in Humacyte by 24.1% in the 2nd quarter. ProShare Advisors LLC now owns 31,493 shares of the company’s stock valued at $66,000 after buying an additional 6,106 shares during the last quarter. Concurrent Investment Advisors LLC lifted its stake in Humacyte by 17.5% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 51,115 shares of the company’s stock valued at $107,000 after acquiring an additional 7,615 shares in the last quarter. Finally, Beacon Pointe Advisors LLC lifted its stake in Humacyte by 28.6% during the 2nd quarter. Beacon Pointe Advisors LLC now owns 36,000 shares of the company’s stock valued at $75,000 after acquiring an additional 8,000 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Trading Down 6.3%

HUMA opened at $1.05 on Friday. The company has a fifty day moving average price of $1.16 and a two-hundred day moving average price of $1.58. Humacyte has a 1-year low of $0.91 and a 1-year high of $4.85. The company has a market cap of $196.63 million, a P/E ratio of -4.57 and a beta of 1.93. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. The company had revenue of $0.75 million for the quarter, compared to the consensus estimate of $0.92 million. Analysts predict that Humacyte will post -1.27 EPS for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.